The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PEARL
- 28 Nov 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 28 Nov 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.